Literature DB >> 2314744

Survey of neurological problems with amiodarone in the New Zealand Intensive Medicines Monitoring Programme.

D M Coulter1, I R Edwards, R L Savage.   

Abstract

Early in the monitoring of amiodarone it was evident that neurological events were unexpectedly frequent. A survey was then undertaken to measure the frequency of such events and to gain some impression of their clinical importance. The method of survey was the completion of questionnaires by doctors when patients were being reviewed. There was a 63.6% response rate and questionnaires were evaluated for 408 patients. There were 192 events assessed as being adverse reactions from a group of nine types of neurological events in 112 patients. Paraesthesiae, ataxia, vertigo and tremor were the most common (7-9%). The overall rate of neurological reactions was 27.5%. The individual reactions are examined as are dose relationships.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2314744

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  10 in total

Review 1.  Drug-induced cerebellar ataxia: a systematic review.

Authors:  J van Gaalen; F G Kerstens; R P P W M Maas; L Härmark; B P C van de Warrenburg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

2.  Severe muscle cramps after intravenous administration of amiodarone--a novel, potentially dose-dependent adverse effect.

Authors:  Sandeep A Saha
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

3.  Causality Assessment in Pharmacovigilance: Still a Challenge.

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2017-05       Impact factor: 5.606

4.  Amiodarone-associated bilateral vestibulopathy.

Authors:  Robert Gürkov; Leonardo Manzari; Alexander Blödow; Angela Wenzel; Dusan Pavlovic; Leonal Luis
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-27       Impact factor: 2.503

5.  A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).

Authors:  P W Beggs; D W Clark; S M Williams; D M Coulter
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

Review 6.  [Clinical aspects of treatment with amiodarone].

Authors:  W Haverkamp; C Israel; A Parwani
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-09

Review 7.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

8.  Tremor: clinical phenomenology and assessment techniques.

Authors:  Christopher W Hess; Seth L Pullman
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-06-28

Review 9.  Insights into Pathophysiology from Medication-induced Tremor.

Authors:  John C Morgan; Julie A Kurek; Jennie L Davis; Kapil D Sethi
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2017-11-22

Review 10.  Amiodarone: A Newly Discovered Association with Bilateral Vestibulopathy.

Authors:  Robert Gürkov
Journal:  Front Neurol       Date:  2018-03-06       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.